.Merck defeats incomes desires, rears sales outlook on tough requirement for top medicines like Keytruda CNBCMerck & Co. (MRK United States) Trumps Revenue Forecasts as Keytruda Sales Growth BloombergMerck Sell: Pharma Titan Posts Solid End Results, However Outlook Drops Short Real estate investor's Service DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats income as well as sales assumptions amid Keytruda advantage, yet delivers mixed full-year overview MarketWatch.